Gene Biotherapeutics, Inc.
CRXM · OTC
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.02 | 0.02 |
| FCF Yield | -124.01% | -5.12% | -61.06% | -74.34% |
| EV / EBITDA | -1.42 | -4.88 | -3.83 | -1.30 |
| Quality | ||||
| ROIC | 38.15% | 22.45% | 11.24% | 53.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.74 | -0.18 | 0.82 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -728.54% | 69.62% | 57.50% | 51.61% |
| Safety | ||||
| Net Debt / EBITDA | -0.69 | -1.44 | -2.19 | -0.59 |
| Interest Coverage | -21.99 | -19.12 | -12.98 | -102.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -149,852.80 | -6,067.92 | -10,730.09 | -10,329.24 |